Log in to save to my catalogue

A real‐life pilot study of the clinical application of pharmacogenomics testing on saliva in epileps...

A real‐life pilot study of the clinical application of pharmacogenomics testing on saliva in epileps...

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_89748850918e4af5aae8b4008c9d68b6

A real‐life pilot study of the clinical application of pharmacogenomics testing on saliva in epilepsy

About this item

Full title

A real‐life pilot study of the clinical application of pharmacogenomics testing on saliva in epilepsy

Publisher

United States: John Wiley & Sons, Inc

Journal title

Epilepsia open, 2023-09, Vol.8 (3), p.1142-1150

Language

English

Formats

Publication information

Publisher

United States: John Wiley & Sons, Inc

More information

Scope and Contents

Contents

Response to antiseizure medications (ASMs) can be influenced by several gene polymorphisms, causing either lower efficacy or higher occurrence of adverse drug reactions (ADRs). We investigated the clinical utility of salivary pharmacogenomic testing on epilepsy patients. A commercialized pharmacogenomic salivary test was performed in a cohort of ep...

Alternative Titles

Full title

A real‐life pilot study of the clinical application of pharmacogenomics testing on saliva in epilepsy

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_doaj_primary_oai_doaj_org_article_89748850918e4af5aae8b4008c9d68b6

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_89748850918e4af5aae8b4008c9d68b6

Other Identifiers

ISSN

2470-9239

E-ISSN

2470-9239

DOI

10.1002/epi4.12717

How to access this item